DK1504035T6 - Antistoffer, der er specifikke for human CD22, og deres terapeutiske og diagnostiske anvendelser - Google Patents

Antistoffer, der er specifikke for human CD22, og deres terapeutiske og diagnostiske anvendelser Download PDF

Info

Publication number
DK1504035T6
DK1504035T6 DK03718974.3T DK03718974T DK1504035T6 DK 1504035 T6 DK1504035 T6 DK 1504035T6 DK 03718974 T DK03718974 T DK 03718974T DK 1504035 T6 DK1504035 T6 DK 1504035T6
Authority
DK
Denmark
Prior art keywords
antibody molecule
seq
ser
gly
thr
Prior art date
Application number
DK03718974.3T
Other languages
English (en)
Other versions
DK1504035T3 (da
Inventor
Andrew George Popplewell
Simon Peter Tickle
Heather Margaret Ladyman
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9935990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1504035(T6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of DK1504035T3 publication Critical patent/DK1504035T3/da
Application granted granted Critical
Publication of DK1504035T6 publication Critical patent/DK1504035T6/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (31)

1. Antistofmolekyle med specificitet for human CD22 omfattende en tung kæde, hvor det variable domæne omfatter SEQ ID NO: 1 for CDR-H1, sekvensen GINPGNNYATYRRKFQG af gH7 i figur 6 eller SEQ ID NO: 2 eller SEQ ID NO: 13 eller SEQ ID NO: 15 eller SEQ ID NO: 16 for CDR-H2 og SEQ ID NO:3 for CDR-H3 og en let kæde, hvor det variable domæne omfatter SEQ ID NO:4 for CDR-L1, SEQ ID NO:5 for CDR-L2 og SEQ ID NO:6 for CDR-L3.
2. Antistofmolekyle ifølge krav 1 omfattende sekvensen GINPGNNYATYRRKFQG af gH7 i figur 6 for CDR-H2.
3. Antistofmolekyle ifølge et hvilket som helst af kravene 1 til 2, som er et ved CDR-grafting fremstillet antistofmolekyle.
4. Antistofmolekyle ifølge krav 3, hvor det variable domæne omfatter humane acceptor-skeletregioner og ikke-humane donor-CDRer.
5. Antistofmolekyle ifølge krav 4, hvor de humane acceptor-skeletregioner af det variable domæne i den tunge kæde er baseret på SEQ ID NO: 21 og 22 og omfatter donorrester i positionerne 1, 28, 48, 71 og 93, nummereret ifølge Kabat, hvilke svarer til resterne henholdsvis 1,28, 48, 72 og 97 i SEQ ID NO:8.
6. Antistofmolekyle ifølge krav 5 yderligere omfattende donorrester i positionerne 67 og 69, nummereret ifølge Kabat, hvilke svarer til resterne henholdsvis 68 og 70 i SEQ ID NO:8.
7. Antistofmolekyle ifølge et hvilket som helst af kravene 4 til 6, hvor de humane acceptor-skeletregioner i det variable domæne i den lette kæde er baseret på SEQ ID NO: 17 og 18 og omfatter donorrester i positionerne 2, 4, 37, 38, 45 og 60, nummereret ifølge Kabat, hvilke svarer til resterne henholdsvis 2, 4, 42, 43, 50 og 65 i SEQ ID NO:7.
8. Antistofmolekyle ifølge krav 7 yderligere omfattende en donorrest i position 3, nummereret ifølge Kabat, hvilken svarer til resten i den position i SEQ ID NO:7.
9. Antistofmolekyle med specificitet for human CD22 omfattende en tung kæde i henhold til enten krav 5 eller krav 6, og en let kæde i henhold til enten krav 7 eller krav 8.
10. Antistofmolekyle ifølge et hvilket som helst af kravene 1 til 9, omfattende SEQ ID NO:19 (den variable region af den lette kæde 5/44-gL1) og SEQ ID NO:27 (den variable region af den tunge kæde 5/44-gH7).
11. Antistofmolekyle med specificitet for human CD22, som har en let kæde omfattende sekvensen givet i SEQ ID NO:28 og en tung kæde omfattende sekvensen givet i SEQ ID NO:30.
12. Antistofmolekyle med specificitet for human CD22, som har en let kæde bestående af sekvensen givet i SEQ ID NO:28 og en tung kæde bestående af sekvensen givet i SEQ ID NO:30.
13. Antistof ifølge krav 1, som er murint, monoklonalt anti-CD22-antistof 5/44, hvor det variable domæne af den lette kæde har sekvensen givet i SEQ ID NO: 7, og det variable domæne af den tunge kæde har sekvensen givet i SEQ ID NO: 8.
14. Antistofmolekyle ifølge krav 1, som er et kimært antistofmolekyle omfattende sekvenserne af de variable domæner af den lette og tunge kæde af det monoklonale antistof ifølge krav 18, gengivet i henholdsvis SEQ ID NO:7 og SEQ ID NO:8.
15. DNA-sekvens kodende for den tunge kæde af et antistofmolekyle ifølge et hvilket som helst af kravene 1 til 14.
16. DNA-sekvens kodende for den lette kæde af et antistofmolekyle ifølge et hvilket som helst af kravene 1 til 14.
17. DNA-sekvens kodende for den tunge kæde og den lette kæde af et antistofmolekyle ifølge et hvilket som helst af kravene 1 til 14.
18. Klonings- eller ekspressionsvektor omfattende en DNA-sekvens ifølge et hvilket som helst af kravene 15 til 17.
19. Værtscelle omfattende en klonings- eller ekspressionsvektor ifølge krav 18.
20. Antistofmolekyle ifølge et hvilket som helst af kravene 1 til 14 eller en DNA-sekvens ifølge et hvilket som helst af kravene 15 til 17 til anvendelse i terapi.
21. Antistofmolekyle ifølge et hvilket som helst af kravene 1 til 14 eller 20, med specificitet for human CD22, eller en DNA-sekvens ifølge et hvilket som helst af kravene 15 til 17 eller 20 til anvendelse i behandling af en patologi, der er medieret af celler, der udtrykker CD22.
22. Antistofmolekyle ifølge et hvilket som helst af kravene 1 til 14, 20 eller 21 eller en DNA-sekvens ifølge et hvilket som helst af kravene 15 til 17, 20 eller 21 til anvendelse i behandling af maligne lymfomer.
23. Antistofmolekyle eller DNA-sekvens ifølge krav 22, hvor de maligne lymfomer er Non-Hodgkin's lymfomer.
24. Anvendelse af et antistofmolekyle ifølge et hvilket som helst af kravene 1 til 14, med specificitet for human CD22, eller anvendelse af en DNA-sekvens ifølge et hvilket som helst af kravene 15 til 17 til fremstilling af et lægemiddel til behandling af en patologi, der er medieret af celler udtrykkende CD22.
25. Anvendelse ifølge krav 24, hvor patologien er malignt lymfom.
26. Anvendelse ifølge krav 25, hvor det maligne lymfom er Non-Hodgkin's lymfom.
27. Terapeutisk eller diagnostisk sammensætning omfattende et antistofmolekyle ifølge et hvilket som helst af kravene 1 til 14 eller en DNA-sekvens ifølge et hvilket som helst af kravene 15 til 17.
28. Terapeutisk sammensætning omfattende antistofmolekylet ifølge et hvilket som helst af kravene 1 til 14, hvori antistoffet har et toxin bundet til sig ved en covalent brodannende struktur, og omfattende en farmaceutisk acceptabel excipiens, diluent eller bærer.
29. Terapeutisk eller diagnostisk sammensætning ifølge krav 27 yderligere omfattende anti-T celle-, anti-IFNy- eller anti-LPS-antistoffer eller non-antistof-ingredienser, såsom xanthiner.
30. Fremgangsmåde til fremstilling af et antistofmolekyle ifølge et hvilket som helst af kravene 1 til 14 omfattende dyrkning af en værtscelle ifølge krav 19 under betingelser, der er egnede til at føre til ekspression af protein fra DNA kodende for antistofmolekylet, og isolering af antistofmolekylet.
31. Fremgangsmåde til fremstilling af en terapeutisk eller diagnostisk sammensætning ifølge et hvilket som helst af kravene 27 eller 29, omfattende at blande et antistofmolekyle ifølge et hvilket som helst af kravene 1 til 14 sammen med en farmaceutisk acceptabel excipiens, diluent eller bærer.
DK03718974.3T 2002-05-02 2003-05-02 Antistoffer, der er specifikke for human CD22, og deres terapeutiske og diagnostiske anvendelser DK1504035T6 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0210121.0A GB0210121D0 (en) 2002-05-02 2002-05-02 Biological products
PCT/GB2003/001934 WO2003093320A2 (en) 2002-05-02 2003-05-02 Antibodies specific for human cd22 and their therapeuatic and digagnostic uses

Publications (2)

Publication Number Publication Date
DK1504035T3 DK1504035T3 (da) 2010-06-07
DK1504035T6 true DK1504035T6 (da) 2018-03-12

Family

ID=9935990

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03718974.3T DK1504035T6 (da) 2002-05-02 2003-05-02 Antistoffer, der er specifikke for human CD22, og deres terapeutiske og diagnostiske anvendelser

Country Status (34)

Country Link
US (8) US7355011B2 (da)
EP (1) EP1504035B9 (da)
JP (3) JP4486494B2 (da)
KR (3) KR101156796B1 (da)
CN (3) CN100384878C (da)
AT (1) ATE462729T3 (da)
AU (1) AU2003223007C1 (da)
BE (1) BE2017C068I2 (da)
CA (1) CA2484420C (da)
CO (1) CO5631451A2 (da)
CY (3) CY1110134T1 (da)
DE (1) DE60331910D1 (da)
DK (1) DK1504035T6 (da)
EC (1) ECSP045470A (da)
ES (1) ES2341708T7 (da)
FR (1) FR17C1062I2 (da)
GB (1) GB0210121D0 (da)
HU (2) HUS1700056I1 (da)
IL (1) IL164923A (da)
LT (2) LTC1504035I2 (da)
LU (2) LUC00057I2 (da)
MX (1) MXPA04010787A (da)
NL (1) NL300920I2 (da)
NO (3) NO336201B3 (da)
NZ (1) NZ536757A (da)
PL (1) PL218433B1 (da)
PT (1) PT1504035E (da)
RU (1) RU2342401C2 (da)
SG (1) SG161744A1 (da)
SI (1) SI1504035T1 (da)
TW (1) TWI324161B (da)
UA (1) UA92580C2 (da)
WO (1) WO2003093320A2 (da)
ZA (1) ZA200408851B (da)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7355012B2 (en) 2001-09-26 2008-04-08 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
WO2003072736A2 (en) 2002-02-21 2003-09-04 Duke University Reagents and treatment methods for autoimmune diseases
SG187991A1 (en) 2002-05-02 2013-03-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
TW200630106A (en) * 2004-10-08 2006-09-01 Wyeth Corp Immunotherapy of autoimmune disorders
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
EP1999148B8 (en) * 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
JP2009532336A (ja) * 2006-03-06 2009-09-10 メディミューン，エルエルシー ヒト化抗ｃｄ２２抗体、並びに腫瘍、移植及び自己免疫疾患の治療におけるこれらの使用
EP2032606B1 (en) * 2006-05-30 2013-11-27 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US8481683B2 (en) 2006-12-01 2013-07-09 Medarex, Inc. Human antibodies that bind CD22 and uses thereof
WO2009124109A1 (en) * 2008-04-04 2009-10-08 The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services Human monoclonal antibodies specific for cd22
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
JP5996429B2 (ja) 2009-09-03 2016-09-21 ジェネンテック， インコーポレイテッド 関節リウマチの治療、診断及びモニターするための方法
WO2012097333A2 (en) 2011-01-14 2012-07-19 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
MX353143B (es) 2011-02-28 2017-12-20 Genentech Inc Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b.
MX361533B (es) * 2012-04-26 2018-12-07 Bioatla Llc Anticuerpos anti-cd22.
SG10201708959WA (en) 2012-07-03 2017-11-29 Univ Washington Antibodies to tau
EP3539563A1 (en) 2012-07-19 2019-09-18 Redwood Bioscience, Inc. Antibody specific for cd22 and methods of use thereof
RU2658485C2 (ru) 2012-10-24 2018-06-21 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы м971
CN103214578B (zh) * 2013-05-10 2014-05-28 北京东方百泰生物科技有限公司 一种新型的人源化抗cd22抗体
JP2016540826A (ja) 2013-11-04 2016-12-28 ファイザー・インク 抗ｅｆｎａ４抗体−薬物コンジュゲート
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
TWI734975B (zh) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
JP6961490B2 (ja) * 2015-04-08 2021-11-05 ノバルティス アーゲー Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601077D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
EP3373937B1 (en) 2015-11-09 2021-12-22 R.P. Scherer Technologies, LLC Anti-cd22 antibody-maytansine conjugates and methods of use thereof
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
JP2019515677A (ja) 2016-04-26 2019-06-13 アール．ピー．シェーラー テクノロジーズ エルエルシー 抗体複合体ならびにそれを作製および使用する方法
GB201610512D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
PT3528787T (pt) 2016-10-21 2026-03-11 Amgen Inc Formulações farmacêuticas e métodos para produzir as mesmas
EP3774919A4 (en) 2018-03-30 2021-12-29 Eureka Therapeutics, Inc. Constructs targeting cd22 and uses thereof
CA3177230A1 (en) * 2020-04-02 2021-10-07 Nanjing Iaso Biotherapeutics Co., Ltd. Fully human anti-human cd22 chimeric antigen receptor and application thereof
WO2022042494A1 (zh) * 2020-08-27 2022-03-03 深圳市菲鹏生物治疗股份有限公司 Cd22抗体及其应用
WO2022262783A1 (zh) * 2021-06-16 2022-12-22 西安宇繁生物科技有限责任公司 抗cd22的全人源抗体或其抗原结合片段及其制备方法和应用
JP2024534148A (ja) * 2021-08-27 2024-09-18 ペプトロン インコーポレイテッド 新規抗ｍｕｃ１抗体およびその用途
CN119751680A (zh) * 2021-12-06 2025-04-04 重庆精准生物技术有限公司 靶向cd22的抗原结合片段和单链抗体及其应用
WO2024102693A2 (en) 2022-11-07 2024-05-16 Xencor, Inc. Il-18-fc fusion proteins

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957362A (en) * 1972-10-02 1976-05-18 Corneal Sciences, Inc. Hydrogels and articles made therefrom
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5134075A (en) * 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DK0489149T3 (da) * 1990-06-27 2001-12-27 Univ Princeton Prober til påvisning af mutant P53
CA2082160C (en) * 1991-03-06 2003-05-06 Mary M. Bendig Humanised and chimeric monoclonal antibodies
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5714340A (en) * 1992-12-22 1998-02-03 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassay elements having a receptor zone
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
HU220799B1 (hu) 1994-01-25 2002-05-28 Elan Pharmaceuticals, Inc. Humanizált antitestek VLA-4 leukocita adhéziós molekula ellen
DE69534530T2 (de) * 1994-08-12 2006-07-06 Immunomedics, Inc. Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
ATE201445T1 (de) 1994-08-12 2001-06-15 Myriad Genetics Inc Mutationen des mit 17q verbundenen ovarial- und brustkrebs empfindlichkeitsgens
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) * 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0977590A4 (en) * 1996-11-01 2001-03-14 Smithkline Beecham Corp HUMAN MONOCLONAL ANTIBODIES
US20020141990A1 (en) * 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US7541034B1 (en) * 1997-03-20 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Services Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
CA2635352C (en) 1997-06-13 2012-09-11 Genentech, Inc. Stabilized antibody formulation
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
KR100345463B1 (ko) * 1998-11-19 2003-01-08 주)녹십자 B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
DE60042785D1 (de) * 1999-06-09 2009-10-01 Immunomedics Inc Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
SI1232392T1 (en) * 1999-10-12 2003-10-31 Connex Gesellschaft Zur Optimierung Von Forschung Und Improved method for the detection of acid resistant bacteria of the genus helicobacter in stool
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
AU6461201A (en) * 2000-07-12 2002-01-21 Idec Pharma Corp Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
CN1205479C (zh) * 2000-10-31 2005-06-08 杨梦甦 免疫学诊断蛋白芯片制备方法
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
SG187991A1 (en) * 2002-05-02 2013-03-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
EP1999148B8 (en) * 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease

Also Published As

Publication number Publication date
JP5920934B2 (ja) 2016-05-18
LUC00057I2 (da) 2018-02-26
CY2017045I2 (el) 2019-11-27
CN101134779B (zh) 2013-03-13
DK1504035T3 (da) 2010-06-07
LUC00057I1 (da) 2017-12-27
LTPA2017043I1 (lt) 2018-01-10
CY2017046I2 (el) 2018-12-12
LUC00058I1 (da) 2017-12-27
ES2341708T3 (es) 2010-06-25
CN103172742B (zh) 2016-05-11
TW200307690A (en) 2003-12-16
UA92580C2 (ru) 2010-11-25
TWI324161B (en) 2010-05-01
JP4486494B2 (ja) 2010-06-23
RU2004135103A (ru) 2005-10-27
MXPA04010787A (es) 2005-03-07
US7355011B2 (en) 2008-04-08
EP1504035B9 (en) 2018-10-17
JP2010022372A (ja) 2010-02-04
KR101238970B1 (ko) 2013-03-04
DE60331910D1 (de) 2010-05-12
US20210371547A1 (en) 2021-12-02
NL300920I1 (da) 2018-01-03
US7919606B2 (en) 2011-04-05
CO5631451A2 (es) 2006-04-28
LUC00058I2 (da) 2018-02-26
SI1504035T1 (sl) 2010-07-30
CN101134779A (zh) 2008-03-05
CA2484420C (en) 2014-09-16
ES2341708T7 (es) 2018-04-11
NO2017069I1 (no) 2017-12-21
US20110165659A1 (en) 2011-07-07
FR17C1062I2 (fr) 2020-05-29
CN1662558A (zh) 2005-08-31
EP1504035B1 (en) 2010-03-31
SG161744A1 (en) 2010-06-29
EP1504035B8 (en) 2018-02-28
BE2017C068I2 (da) 2022-08-09
WO2003093320A3 (en) 2004-02-05
KR20110004463A (ko) 2011-01-13
US20170145114A1 (en) 2017-05-25
NL300920I2 (nl) 2021-04-15
JP2013230158A (ja) 2013-11-14
IL164923A (en) 2012-03-29
CA2484420A1 (en) 2003-11-13
FR17C1062I1 (da) 2018-02-16
ZA200408851B (en) 2006-01-25
KR101156796B1 (ko) 2012-06-21
AU2003223007A1 (en) 2003-11-17
RU2342401C2 (ru) 2008-12-27
KR20050025167A (ko) 2005-03-11
AU2003223007C1 (en) 2019-08-08
PL373277A1 (en) 2005-08-22
US20070059307A1 (en) 2007-03-15
HK1186479A1 (zh) 2014-03-14
NZ536757A (en) 2006-06-30
HUS1700055I1 (hu) 2018-07-30
LTC1504035I2 (lt) 2022-04-11
HUS1700056I1 (hu) 2018-07-30
JP2006506955A (ja) 2006-03-02
US20160326247A1 (en) 2016-11-10
US20100021995A1 (en) 2010-01-28
CN103172742A (zh) 2013-06-26
HK1071762A1 (en) 2005-07-29
NO336201B1 (no) 2015-06-15
CY2017046I1 (el) 2018-12-12
KR20120127513A (ko) 2012-11-21
NO336201B3 (no) 2015-06-15
AU2003223007B2 (en) 2009-07-16
KR101386376B1 (ko) 2014-04-16
CN100384878C (zh) 2008-04-30
IL164923A0 (en) 2005-12-18
US20030235869A1 (en) 2003-12-25
NO20044742L (no) 2004-12-22
CY2017045I1 (el) 2019-11-27
JP5377173B2 (ja) 2013-12-25
US8895714B2 (en) 2014-11-25
CY1110134T1 (el) 2015-01-14
PT1504035E (pt) 2010-06-07
EP1504035A2 (en) 2005-02-09
PL218433B1 (pl) 2014-12-31
EP1504035B3 (en) 2017-12-20
ECSP045470A (es) 2005-01-28
NO2017068I1 (no) 2017-12-21
WO2003093320A2 (en) 2003-11-13
GB0210121D0 (en) 2002-06-12
ATE462729T3 (de) 2010-04-15
LTPA2017044I1 (lt) 2018-01-10
US20120302739A1 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
DK1504035T6 (da) Antistoffer, der er specifikke for human CD22, og deres terapeutiske og diagnostiske anvendelser
HK1071762B (en) Antibodies specific for human cd22 and their therapeutic and diagnostic uses
BRPI0309730B1 (pt) Molécula de anticorpo possuindo especificidade para cd22 humana, sequência de dna, vetor de expressão ou clonagem, célula hospedeira, uso da molécula de anticorpo ou da sequência de dna, composição diagnóstica ou terapêutica, processo para a produção de uma molécula de anticorpo, processo para a preparação de uma composição diagnóstica ou terapêutica
HK1186479B (en) Antibodies specific for human cd22 and their therapeutic and diagnostic uses